透明细胞肾细胞癌:多期MDCT识别Y染色体缺失
研究纳入2000年10月至2013年8月术前接受四期肾脏肿块MDCT的43例男性透明细胞肾细胞癌患者,比较Y染色体缺失组与未缺失组的绝对及相对强化程度。两组均于皮髓质期达峰值强化,但Y染色体缺失组肾实质期相对强化显著更低(均值-8.9 vs 8.4,p=0.013)。以相对肾实质期强化阈值-1.6识别Y染色体缺失,准确度70%(30/43)、敏感度73%(16/22)、特异度67%(14/21)。
要点
- Y染色体缺失的透明细胞肾细胞癌肾实质期相对强化更低(-8.9 vs 8.4,p=0.013)。
- 以相对肾实质期强化阈值-1.6识别Y染色体缺失,准确度70%(30/43)。
- 多期MDCT强化可能有助于识别透明细胞肾细胞癌的Y染色体缺失。
核心结论
- 多期MDCT强化可能有助于识别透明细胞肾细胞癌中的Y染色体缺失,该结果需在大型前瞻性试验中验证。
研究设计与样本
- 研究纳入43例男性透明细胞肾细胞癌,均于2000年10月至2013年8月术前行四期肾脏肿块MDCT;在轴位图像上对整个病灶进行分割,由计算机辅助检测算法在每个期相选取病灶内直径0.5 cm的最大衰减区域,并在每个期相于未受累肾皮质手动放置直径0.5 cm的ROI;相对强化计算公式为[(病灶最大衰减-皮质衰减)/皮质衰减]×100,各期绝对衰减与相对强化采用t检验比较。
诊断标准与关键数值
- Y染色体缺失组与未缺失组均于皮髓质期达峰值强化;Y染色体缺失组肾实质期相对强化均值为-8.9,未缺失组为8.4,差异有统计学意义(p=0.013);以相对肾实质期强化阈值-1.6识别Y染色体缺失,准确度70%(30/43)、敏感度73%(16/22)、特异度67%(14/21)。
临床应用与阅片要点
- 作者认为多期MDCT强化可能有助于识别透明细胞肾细胞癌中的Y染色体缺失,并指出该结果需在大型前瞻性试验中验证。
局限性
- 作者指出该结果需在大型前瞻性试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The objective of our study was to investigate whether multiphasic MDCT enhancement can help identify clear cell renal cell carcinomas (RCCs) with the loss of the Y chromosome.
MATERIALS AND METHODS: We derived a cohort of 43 clear cell RCCs in men who underwent preoperative four-phase renal mass MDCT from October 2000 to August 2013. Each lesion was segmented in its entirety on axial images. A computer-assisted detection algorithm selected a 0.5-cm-diameter region of maximal attenuation within each lesion in each phase. A 0.5-cm-diameter ROI was manually placed on uninvolved renal cortex in each phase. The relative attenuation of each lesion was calculated as follows: [(maximal lesion attenuation - cortex attenuation) / cortex attenuation] × 100. Absolute attenuation and relative attenuation in each phase were compared using t tests.
RESULTS: Both clear cell RCCs with the loss of the Y chromosome and clear cell RCCs without the loss of the Y chromosome exhibited peak enhancement in the corticomedullary phase. However, relative nephrographic attenuation of clear cell RCCs with the loss of Y was significantly less than that of clear cell RCCs without the loss of Y (mean, -8.9 vs 8.4 respectively; p = 0.013). A relative nephrographic attenuation threshold of -1.6 identified the loss of Y with an accuracy of 70% (30/43), sensitivity of 73% (16/22), and specificity of 67% (14/21).
CONCLUSION: Multiphasic MDCT enhancement may assist in identifying the loss of the Y chromosome in clear cell RCCs; this result should be validated in a large prospective trial.
引用
- Young JR, Coy H, Douek M, et al. Clear Cell Renal Cell Carcinoma: Identifying the Loss of the Y Chromosome on Multiphasic MDCT. AJR Am J Roentgenol. 2017. PMID: 28504543. doi:10.2214/AJR.16.17010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。